X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
X4 Pharmaceuticals (Nasdaq: XFOR), a biotechnology company focused on rare immune system diseases, has scheduled its first-quarter 2025 financial results announcement and corporate update for May 1, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT on the same day.
Investors and interested parties can access the conference call by dialing 1-800-343-4849 (US) or 1-203-518-9848 (International) using the conference ID: X4PHARMA. A live webcast will be available through X4's investor relations website, with a replay accessible after the call.
X4 Pharmaceuticals (Nasdaq: XFOR), un'azienda biotecnologica specializzata in malattie rare del sistema immunitario, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per il 1 maggio 2025. La società terrà una conference call e una diretta web alle 8:30 EDT dello stesso giorno.
Investitori e interessati potranno partecipare alla conference call chiamando il numero 1-800-343-4849 (USA) o 1-203-518-9848 (internazionale) utilizzando l'ID conferenza: X4PHARMA. La diretta web sarà disponibile sul sito delle relazioni con gli investitori di X4, con la possibilità di rivederla in seguito.
X4 Pharmaceuticals (Nasdaq: XFOR), una empresa biotecnológica centrada en enfermedades raras del sistema inmunológico, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización corporativa para el 1 de mayo de 2025. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. EDT del mismo día.
Los inversores y partes interesadas pueden acceder a la conferencia llamando al 1-800-343-4849 (EE.UU.) o al 1-203-518-9848 (internacional) usando el ID de conferencia: X4PHARMA. La transmisión en vivo estará disponible a través del sitio web de relaciones con inversores de X4, con una repetición accesible después de la llamada.
X4 Pharmaceuticals (나스닥: XFOR)는 희귀 면역 질환에 집중하는 생명공학 회사로, 2025년 1분기 재무 결과 발표 및 기업 업데이트를 2025년 5월 1일에 예정하고 있습니다. 회사는 같은 날 오전 8시 30분 EDT에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자 및 관심 있는 분들은 1-800-343-4849 (미국) 또는 1-203-518-9848 (국제) 번호로 컨퍼런스 ID: X4PHARMA를 사용해 컨퍼런스 콜에 참여할 수 있습니다. 웹캐스트는 X4 투자자 관계 웹사이트에서 생중계되며, 콜 종료 후 다시보기 서비스도 제공됩니다.
X4 Pharmaceuticals (Nasdaq : XFOR), une entreprise de biotechnologie spécialisée dans les maladies rares du système immunitaire, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une mise à jour d'entreprise pour le 1er mai 2025. La société tiendra une conférence téléphonique et une webdiffusion le même jour à 8h30 EDT.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en composant le 1-800-343-4849 (États-Unis) ou le 1-203-518-9848 (international) en utilisant l'ID de conférence : X4PHARMA. Une webdiffusion en direct sera disponible via le site des relations investisseurs de X4, avec un replay accessible après l'appel.
X4 Pharmaceuticals (Nasdaq: XFOR), ein Biotechnologieunternehmen, das sich auf seltene Erkrankungen des Immunsystems spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 und ein Unternehmensupdate für den 1. Mai 2025 geplant. Am selben Tag findet um 8:30 Uhr EDT eine Telefonkonferenz und ein Webcast statt.
Investoren und Interessierte können an der Telefonkonferenz teilnehmen, indem sie 1-800-343-4849 (USA) oder 1-203-518-9848 (international) anrufen und die Konferenz-ID: X4PHARMA verwenden. Ein Live-Webcast ist über die Investor-Relations-Website von X4 verfügbar, mit einer Aufzeichnung, die nach dem Anruf abrufbar ist.
- None.
- None.
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025.
The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the conclusion of the call, a webcast replay will be available on the website.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
X4 Media Contact:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com
FAQ
When will X4 Pharmaceuticals (XFOR) release Q1 2025 earnings?
How can investors join X4 Pharmaceuticals' Q1 2025 earnings call?
Will there be a replay available for XFOR's Q1 2025 earnings call?
What time is X4 Pharmaceuticals' Q1 2025 earnings call?
